Regeneron: DB-OTO Results in Sustained Improvement in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
October 14, 2025
0
The Great Story from Regerneron Pharmaceuticals Regeneron Pharmaceuticals (REGN) announced updated data for the Company’s investigational gene therapy DB-OTO for profound genetic hearing loss due to variants of the otoferlin (OTOF) gene were. The investigation has been published in The New England Journal of Medicine and presented during oral presentation at the annual American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNSF) meeting. The latest results …
